Crewe Advisors LLC Buys 8,700 Shares of Geron Co. (NASDAQ:GERN)

Crewe Advisors LLC boosted its stake in Geron Co. (NASDAQ:GERN) by 870.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,700 shares of the biopharmaceutical company’s stock after acquiring an additional 8,700 shares during the period. Crewe Advisors LLC’s holdings in Geron were worth $32,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Kingsview Wealth Management LLC purchased a new position in Geron during the first quarter valued at $34,000. Vishria Bird Financial Group LLC lifted its position in Geron by 17.7% during the first quarter. Vishria Bird Financial Group LLC now owns 24,265 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 3,650 shares during the period. Fishman Jay A Ltd. MI purchased a new position in shares of Geron in the 1st quarter worth about $165,000. Victory Capital Management Inc. raised its position in shares of Geron by 28.1% in the 4th quarter. Victory Capital Management Inc. now owns 61,909 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 13,596 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Geron by 367.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 62,820 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 49,394 shares during the last quarter. Institutional investors own 73.71% of the company’s stock.

Geron Price Performance

Shares of Geron stock remained flat at $4.29 during trading hours on Thursday. The company’s stock had a trading volume of 7,450,662 shares, compared to its average volume of 11,331,458. The business’s 50 day moving average is $4.32 and its 200 day moving average is $3.30. The company has a market capitalization of $2.54 billion, a price-to-earnings ratio of -12.26 and a beta of 0.48. Geron Co. has a 1-year low of $1.64 and a 1-year high of $5.34. The company has a quick ratio of 3.67, a current ratio of 3.67 and a debt-to-equity ratio of 0.03.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.15 million. Geron had a negative return on equity of 68.16% and a negative net margin of 38,730.00%. Sell-side analysts anticipate that Geron Co. will post -0.35 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Stifel Nicolaus lifted their price target on Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, June 10th. Wedbush reaffirmed an “outperform” rating and issued a $7.00 price target on shares of Geron in a research report on Friday, June 7th. Robert W. Baird lowered Geron from an “outperform” rating to a “neutral” rating and set a $4.50 target price for the company. in a research report on Tuesday, April 30th. Barclays started coverage on Geron in a research report on Monday, June 10th. They issued an “overweight” rating and a $9.00 target price for the company. Finally, Needham & Company LLC boosted their target price on Geron from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Friday, June 7th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.93.

Insider Activity at Geron

In related news, CEO John A. Scarlett sold 600,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $4.00, for a total transaction of $2,400,000.00. Following the completion of the transaction, the chief executive officer now directly owns 600,000 shares in the company, valued at approximately $2,400,000. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Geron news, CEO John A. Scarlett sold 600,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $4.00, for a total value of $2,400,000.00. Following the completion of the transaction, the chief executive officer now directly owns 600,000 shares in the company, valued at approximately $2,400,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Faye Feller sold 287,900 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $4.63, for a total value of $1,332,977.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,562,248 shares of company stock worth $6,808,004. 3.10% of the stock is owned by company insiders.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.